Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs; Draft Guidance for Industry; Correction
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Issuing agencies
Abstract
The Food and Drug Administration (FDA) is correcting a notice entitled "Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs; Draft Guidance for Industry" that appeared in the Federal Register of March 10, 2022. The document omitted the date by which comments on the draft guidance should be submitted to FDA. This error is corrected in this document for clarity.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 55 (Tuesday, March 22, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 55 (Tuesday, March 22, 2022)]
[Notices]
[Pages 16217-16218]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-06006]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2018-D-3462]
Verification Systems Under the Drug Supply Chain Security Act for
Certain Prescription Drugs; Draft Guidance for Industry; Correction
AGENCY: Food and Drug Administration, Department of Health and Human
Services (HHS).
[[Page 16218]]
ACTION: Notice; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is correcting a notice
entitled ``Verification Systems Under the Drug Supply Chain Security
Act for Certain Prescription Drugs; Draft Guidance for Industry'' that
appeared in the Federal Register of March 10, 2022. The document
omitted the date by which comments on the draft guidance should be
submitted to FDA. This error is corrected in this document for clarity.
FOR FURTHER INFORMATION CONTACT: Sarah Venti, Office of Compliance,
Center for Drug Evaluation and Research, Food and Drug Administration,
10903 New Hampshire Ave., Silver Spring, MD 20993-0002, 301-796-3130,
<a href="/cdn-cgi/l/email-protection#f490868193808695979f959a908086959791b4929095da9c9c87da939b82"><span class="__cf_email__" data-cfemail="7612040311020417151d171812020417151336101217581e1e0558111900">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: In the Federal Register of March 10, 2022
(87 FR 13738), appearing on page 13738, in FR Doc. 2022-05018, in the
second column, the DATES section is corrected to read as follows:
DATES: The announcement of the guidance is published in the Federal
Register on March 10, 2022. Although you can comment on any guidance at
any time (see 21 CFR 10.115(g)(5)), to ensure that the Agency considers
your comment on this draft guidance before it begins work on the final
version of the guidance, submit either electronic or written comments
on the draft guidance by May 9, 2022.
Dated: March 17, 2022.
Andi Lipstein Fristedt,
Deputy Commissioner for Policy, Legislation, and International Affairs,
U.S. Food and Drug Administration.
[FR Doc. 2022-06006 Filed 3-21-22; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.